Advertisement

Topics

Clinical Trials About "A Study of RO5045337 in Patients With Solid Tumors" RSS

17:38 EDT 19th March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "A Study of RO5045337 in Patients With Solid Tumors" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "A Study of RO5045337 in Patients With Solid Tumors" on BioPortfolio

We have published hundreds of A Study of RO5045337 in Patients With Solid Tumors news stories on BioPortfolio along with dozens of A Study of RO5045337 in Patients With Solid Tumors Clinical Trials and PubMed Articles about A Study of RO5045337 in Patients With Solid Tumors for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Study of RO5045337 in Patients With Solid Tumors Companies in our database. You can also find out about relevant A Study of RO5045337 in Patients With Solid Tumors Drugs and Medications on this site too.

Showing "Study RO5045337 Patients With Solid Tumors" Clinical Trials 1–25 of 18,000+

Extremely Relevant

A Study of RO5045337 in Patients With Solid Tumors

This open-label, randomized, cross-over study will evaluate the effect of food on the pharmacokinetics of single oral doses of RO5045337 in patients with solid tumors. The anticipated time on study treatment is 3 weeks.


A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors

This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients w ith advanced solid tumors. A first cohort of patients will receive the starting dose of 20mg/m2/day, once daily for 10 days in each 28 day cycle. Subsequent coh orts of patients will receive dose escalations, and possible changes in dosing s chedule, based on tolerability and pharmacokinetic knowledge gained from prior ...

A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery

This open-label study will evaluate efficacy, safety and tolerability of RO5045337 in patients with liposarcoma who are eligible for debulking surgery. Prior to surgery, patients will receive 2-3 cycles of RO5045337, orally for 10 days followed by 18 days of rest per cycle. Anticipated time on study treatment is 3 months. Patients with an incomplete resection may be treated for an additional 3 cycles with RO5045337.


Relevant

A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors

The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors. Safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor metabolism will also be studied. JI-101 is an inhibitor of new blood vessel growth that may provide benefit to patients with solid tumors that have failed standard therapeutic regimens.

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in patients with Advanced Solid Tumors

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

This aim of study to assess the safety and tolerability of SHR7390 and to define the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors. To evaluate the pharmacokinetics of SHR7390 in patients with advanced solid tumors. To study the effects of food on the pharmacokinetic parameters of SHR7390. To assess the antitumor activity of SHR7390 in patients with advanced solid tumors preliminarily and recommend reasonable dosage regimen for the follow-...

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

This is an open label, single arm, dose escalation study of ARQ 197 in patients with advanced solid tumors.

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

The purpose of this study is to determine the DLT, MTD and recommended Phase II dose of ixabepilone in Japanese patients with solid tumors.

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

An open-label dose escalation study of patients with solid tumors treated with STA-9090

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

An open-label dose escalation study of patients with solid tumors treated with STA-9090

Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including Central Nervous System Tumors

This study is a Phase I study using vinblastine and sirolimus in patients with relapsed solid tumors including selected brain tumors and lymphoma. The investigators hypothesis is that the combination administration of weekly vinblastine and sirolimus is safe.

Phase I Study of Indibulin in Patients With Solid Tumors

Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with solid tumors.

Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors

This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.

Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors

The purpose of this study is to assess the safety of the combination of CORT125134, a novel glucocorticoid receptor (GR) antagonist, and nab-paclitaxel in patients with solid tumors and to determine the preliminary efficacy of the combination of CORT125134 and nab-paclitaxel in patients with solid tumors. The structure for the study is a single arm, non-randomized, open-label, multicenter trial with no control group. The study will be conducted at approximately 8 sites with app...

A Study of QBI-139 in Subjects With Advanced Solid Tumors

The purposes of this trial are: - To evaluate the toxicity and tolerability of QBI-139 in patients with advanced refractory solid tumors. - To determine the maximum tolerated dose of QBI-139 in patients with advanced, refractory solid tumors. Patients will receive QBI-139 by IV infusion over at least one hour once weekly for three weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts ...

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors

This is a 4-part, open-label, Phase 1/1b, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; and 4) non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements. The study is designed to explore the safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetics, and antitumor activity of entrectinib.

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.

First in Human Study of IBI310 in Treatment of Patients With Advanced Solid Tumors

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310 in patients with advanced solid tumors.

A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)

This is a study to find a maximum tolerated dose (MTD) and pharmacokinetic (PK) data for ridaforolimus given to participants between the ages of 6 and 17 years with advanced solid tumors. Study-related visits concluded in August 2013. Participants may continue treatment until they meet discontinuation criteria or voluntarily withdraw.

A Study of PD1 Combined With Dc-nk in the Treatment of Solid Tumors

clinical study on the safety and efficacy of PD1 combined with dc-Nk in the treatment of solid tumors

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

The purpose of this study is to determine the safety and tolerability of ME-344 when given in combination with Hycamtin® in patients with solid tumors

Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

This is a Phase 1, nonrandomized, open-label, dose-escalation study of 3-hour IV infusions of RH-1 administered to patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL). Treatment will continue until a patient meets criteria for discontinuation.

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) and efficacy.

Study of TSR-033 With an Anti-PD-1

This is a multicenter, open-label, first-in-human Phase 1 study evaluating TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors in a broad range of solid tumors. Patients with disease types selected for evaluation in this study are expected to derive clinical benefit with addition of an anti-PD-1. The study will be conducted in two parts: dose escalation and cohort expansion.


More From BioPortfolio on "A Study of RO5045337 in Patients With Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement